AVROBIO Inc. (NASDAQ:AVRO) shares traded -1.40% lower at $1.41 on Wall Street last session.
In accordance with the data, 7 analysts cover AVROBIO Inc. (NASDAQ:AVRO). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $6.00 and a low of $2.00, we find $3.00. Given the previous closing price of $1.43, this indicates a potential upside of 109.79 percent. AVRO stock price is now 46.33% away from the 50-day moving average and 50.06% away from the 200-day moving average. The market capitalization of the company currently stands at $61.72M.
It has been rated a hold by 2 analysts and a buy by 4. Brokers who have rated the stock have averaged $3.50 as their price target over the next twelve months.
Insiders disposed of 245,123 shares of company stock worth roughly $0.35 million over the past 1 year. A total of 2.66% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in AVRO stock. A new stake in AVROBIO Inc. shares was purchased by POINT72 ASSET MANAGEMENT, L.P. during the first quarter worth $917,000. VIRTU FINANCIAL LLC invested $57,000 in shares of AVRO during the first quarter. In the first quarter, TANG CAPITAL MANAGEMENT LLC acquired a new stake in AVROBIO Inc. valued at approximately $53,000. SUSQUEHANNA INTERNATIONAL GROUP, LLP acquired a new stake in AVRO for approximately $34,000. CITIGROUP INC purchased a new stake in AVRO valued at around $28,000 in the second quarter. In total, there are 65 active investors with 56.00% ownership of the company’s stock.
AVROBIO Inc. (NASDAQ: AVRO) opened at $1.3600 on Thursday. During the past 12 months, AVROBIO Inc. has had a low of $0.56 and a high of $1.93. As of last week, the company has a debt-to-equity ratio of 0.29, a current ratio of 5.40, and a quick ratio of 5.40. The fifty day moving average price for AVRO is $0.9752 and a two-hundred day moving average price translates $0.9431 for the stock.
The latest earnings results from AVROBIO Inc. (NASDAQ: AVRO) was released for Mar, 2023.
AVROBIO Inc.(AVRO) Company Profile
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company’s pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1, as well as to treat Gaucher disease type 3; AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease; AVR-RD-04, which is in phase 1/2 clinical trial for the treatment of cystinosis; and AVR-RD-05 that is in preclinical stage for the treatment of Hunter syndrome. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
